SCHEMBL5407547

SCHEMBL5407547

Cc1c(OC2CCC(NC(=O)C3CC3)CC2)ccc2[nH]ncc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 6/20 0.43
ABL1 P00519 2/20 0.41
AXL P30530 1/20 0.40
TYRO3 Q06418 1/20 0.40
MERTK Q12866 1/20 0.40
PIK3CD O00329 4/20 0.39
GSK3B P49841 5/20 0.39
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
GSK3A P49840 2/20 0.39
PIM1 P11309 3/20 0.39
PIK3CA P42336 3/20 0.39
PIK3CG P48736 2/20 0.39
PIK3CB P42338 2/20 0.38
MAPK14 Q16539 1/20 0.38
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
TYK2 P29597 2/20 0.38
JAK3 P52333 2/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413500 1.00 MAP4K1 (0.43) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5407543 1.00 MAP4K1 (0.43) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5409381 0.96 POLB (0.40) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5415009 0.96 POLB (0.40) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5409374 0.96 POLB (0.40) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5416473 0.89 CCNA2 (0.43) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5405682 0.89 CCNA2 (0.43) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5405688 0.89 CCNA2 (0.43) MAP4K1ABL1AXLTYRO3MERTK
SCHEMBL5419632 0.89 AXL (0.41) AXLTYRO3MERTKCDK2MAPK14
SCHEMBL5419469 0.89 AXL (0.41) AXLTYRO3MERTKCDK2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA MAP4K1 109/4885ABL1 183/4885AXL 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.